首页> 美国卫生研究院文献>other >The Adequacy of Phosphorus Binder Prescriptions Among American Hemodialysis Patients
【2h】

The Adequacy of Phosphorus Binder Prescriptions Among American Hemodialysis Patients

机译:美国血液透析患者中​​磷粘合剂处方的充分性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Because hemodialysis treatment has a limited ability to remove phosphorus, dialysis patients must restrict dietary phosphorus intake and use phosphorus binding medication. Among patients with restricted dietary phosphorus intake (1000 mg/d), phosphorus binders must bind about 250 mg of excess phosphorus per day and among patients with more typical phosphorus intake (1500 mg/d), binders must bind about 750 mg per day. To determine the phosphorus binding capacity of binder prescriptions among American hemodialysis patients, we undertook a cross-sectional study of a random sample of in-center chronic hemodialysis patients.We obtained data for one randomly selected patient from 244 facilities nationwide. About one-third of patients had hyperphosphatemia (serum phosphorus level > 5.5 mg/dL). Among the 224 patients prescribed binders, the mean phosphorus binding capacity was 256 mg/d (SD 143). 59% of prescriptions had insufficient binding capacity for restricted dietary phosphorus intake, and 100% had insufficient binding capacity for typical dietary phosphorus intake. Patients using two binders had a higher binding capacity than patients using one binder (451 vs. 236 mg/d, p <0.001).A majority of binder prescriptions have insufficient binding capacity to maintain phosphorus balance. Use of two binders results in higher binder capacity. Further work is needed to understand the impact of binder prescriptions on mineral balance and metabolism and to determine the value of substantially increasing binder prescriptions.
机译:由于血液透析治疗的除磷能力有限,因此透析患者必须限制饮食中磷的摄入并使用磷结合药物。在饮食中限制磷摄入量(1000 mg / d)的患者中,磷结合剂每天必须结合约250 mg的过量磷,而在更典型磷摄入量(1500 mg / d)的患者中,结合剂每天必须结合约750 mg。为了确定美国血液透析患者中​​结合剂处方的磷结合能力,我们对中心慢性血液透析患者的随机样本进行了横断面研究,我们从全国244个机构中随机选择了一名患者的数据。约三分之一的患者患有高磷血症(血清磷水平> 5.5 mg / dL)。在224名使用结合剂的患者中,平均磷结合能力为256 mg / d(SD 143)。 59%的处方对限制饮食中的磷摄入量没有足够的结合能力,而100%的处方对典型饮食中的磷摄入量没有足够的结合能力。使用两种结合剂的患者比使用一种结合剂的患者具有更高的结合能力(451 vs. 236 mg / d,p <0.001)。大多数结合剂处方的结合能力不足以维持磷平衡。两种粘合剂的使用导致更高的粘合剂容量。需要进一步的工作来理解粘合剂处方对矿物质平衡和代谢的影响,并确定大量增加粘合剂处方的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号